Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Neuropraxis
Gepubliceerd in: Neuropraxis 1/2014

01-02-2014 | Artikel

Een vernieuwende farmacotherapeutische behandeling voor vrouwen met hypoactive sexual desire disorder

Auteurs: Saskia Poels, Jos Bloemers, Kim van Rooij, Hans Koppeschaar, Berend Olivier, Adriaan Tuiten

Gepubliceerd in: Neuropraxis | Uitgave 1/2014

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Samenvatting

Verminderd seksueel verlangen is de meest voorkomende seksuele klacht bij vrouwen. Dit kan seksuele ontevredenheid veroorzaken, wat een negatieve invloed kan hebben op de kwaliteit van leven. Deze klachten zijn in de DSM-IV geclassificeerd als de diagnose Hypoactive Sexual Desire Disorder (HSDD) en sinds kort ondergebracht in de nieuwe diagnose Female Sexual Interest/Arousal Disorder (FSIAD) in de DSM-5. Op dit moment is er nog geen goedgekeurde medicamenteuze behandeling beschikbaar voor vrouwen met HSDD (FSIAD) terwijl er wel grote behoefte aan is. In onze zoektocht naar adequate medische behandelingsmogelijkheden hebben wij een andere wetenschappelijke aanpak gevolgd dan de grote farmaceutische bedrijven. Op basis van een personalized sexual medicine approach hebben we eerst vastgesteld dat er tussen vrouwen verschillen bestaan in oorzakelijke mechanismen die ten grondslag kunnen liggen aan de seksuele klachten. Dit leidde tot twee onderscheidende mechanismen: een ongevoelig systeem voor seksuele stimuli en een overactief seksueel remsysteem. Gebaseerd op deze onderliggende oorzaken van HSDD zijn twee nieuwe on-demand medicamenteuze behandelingen ontwikkeld. De ene behandeling (testosteron gecombineerd met een fosfodiësterase-type-5-remmer) is ontwikkeld voor vrouwen die lijden aan HSDD als gevolg van een relatief ongevoelig systeem voor seksuele prikkels, terwijl de andere behandeling (testosteron gecombineerd met een 5-HT1A -receptoragonist) is ontwikkeld voor vrouwen die lijden aan HSDD als gevolg van overmatige activatie van het seksuele remsysteem.
vorige artikel Lifelong premature ejaculatie: een neurobiologische hypothese over erectio praecox, hypererotisch toestandsbeeld en detumescentia praecox
volgende artikel Rattenseks als model voor complex seksueel gedrag van mensen
Literatuur
1.
Aleman, A., Bronk, E., Kessels, R.P., Koppeschaar, H.P., Honk J. van (2004). A single administration of testosterone improves visuospatial ability in young women. Psychoneuroendocrinology, 29, 612–617.
2.
American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders. Text Revision. Fourth ed. Washington, DC: American Psychiatric Association;.
3.
American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders. Fifth ed. Washington, DC: American Psychiatric Association.
4.
Anders, S.M. van, Hamilton, L.D., Schmidt, N. & Watson, N.V. (2007). Associations between testosterone secretion and sexual activity in women. Hormones and Behavior, 51, 477–482.
5.
Auger A. (2004). Steroid receptor control of reproductive behavior. Hormones and Behavior, 45, 168–72.
6.
Baglietto, L., Severi, G., English, D.R., Krishnan, K., Hopper, J.L., McLean, C. et al. (2010). Circulating steroid hormone levels and risk of breast cancer for postmenopausal women. Cancer Epidemiology, Biomarkers and Prevention, 19, 492–502.
7.
Basson, R. & Brotto, L.A. (2003). Sexual psychophysiology and effects of sildenafil citrate in oestrogenised women with acquired genital arousal disorder and impaired orgasm: a randomised controlled trial. BJOG, An International Journal of Obstetrics and Gyneacology, 110, 1014–1024.
8.
Beauregard, M., Levesque, J. & Bourgouin, P. (2001). Neural correlates of conscious self-regulation of emotion. The Journal of Neuroscience, 21, RC165.
9.
Bloemers, J., Gerritsen, J., Bults, R., Koppeschaar, H., Everaerd, W., Olivier, B. et al. (2010). Induction of sexual arousal in women under conditions of institutional and ambulatory laboratory circumstances: a comparative study. Journal of Sexual Medicine, 7, 1160–1176.
10.
Bloemers, J., Rooij, K. van, Poels, S., Goldstein, I., Everaerd, W., Koppeschaar, H. et al. (2013). Toward personalized sexual medicine (part 1): integrating the ‘dual control model’ into differential drug treatments for Hypoactive Sexual Desire Disorder and female sexual arousal disorder. Journal of Sexual Medicine, 10, 791–809.
11.
Bos, P.A., Panksepp, J., Bluthe, R.M. & Honk, J.V. (2011). Acute effects of steroid hormones and neuropeptides on human social-emotional behavior: A review of single administration studies. Frontiers in Neuroendocrinology.
12.
Brand, J.S., Schouw, Y.T. van der (2010). Testosterone, SHBG and cardiovascular health in postmenopausal women. International Journal of Impotence Research, 22, 91–104.
13.
Braunstein, G.D. (2007). Safety of testosterone treatment in postmenopausal women. Fertility and Sterility, 88, 1–17.
14.
Braunstein, G.D., Sundwall, D.A., Katz, M., Shifren, J.L., Buster, J.E., Simon, J.A. et al. (2005). Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Archives of Internal Medicine, 165, 1582–1589.
15.
Chamberlain, N.L., Driver, E.D. & Miesfeld, R.L. (1994). The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Research, 22, 3181–3186.
16.
Childress, A.R., Ehrman, R.N., Wang, Z., Li, Y., Sciortino, N., Hakun, J. et al. (2008). Prelude to passion: limbic activation by ‘unseen’ drug and sexual cues. PLoS One, 3, e1506.
17.
Clayton, A.H. (2010). The pathophysiology of hypoactive sexual desire disorder in women. International Journal of Gynecology and Obstetrics, 110, 7–11.
18.
Corbin, J. & Francis, S. (1999). Cyclic GMP phosphodiesterase-5: Target of sildenafil. Journal of Biological Chemistry, 274, 13729–13732.
19.
Cottingham, S.L. & Pfaff, D. (1986). Interconnectedness of steroid-binding hormones: existence and implications. In: Gauten, D., editor. Current Topics in Endocrinology. Berlin: Springer, pp. 223–240.
20.
Dabbs, J.D.M., editor (2000). Heroes, rogues, and lovers: Testosterone and behavior. New York: McGraw-Hill.
21.
Davis, S., Papalia, M.A., Norman, R.J., O’Neill, S., Redelman, M., Williamson, M. et al. (2008). Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: a randomized trial. Annals of Internal Medicine, 148, 569–577.
22.
Davis, S.R, Moreau, M., Kroll, R., Bouchard, C., Panay, N., Gass, M. et al. (2008). Testosterone for low libido in postmenopausal women not taking estrogen. New England Journal of Medicine, 359, 2005–2017.
23.
Davis, S.R., Braunstein, G.D. (2012). Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. Journal of Sexual Medicine, 9, 1134–1148.
24.
Davis, S.R., Hirschberg, A.L., Wagner, L.K., Lodhi, I., Schoultz, B. von (2009). The effect of transdermal testosterone on mammographic density in postmenopausal women not receiving systemic estrogen therapy. Journal of Clinical Endocrinology & Metabolism, 94, 4907–4913.
25.
Davis, S.R., Wolfe, R., Farrugia, H., Ferdinand, A. & Bell, R.J. (2009). The incidence of invasive breast cancer among women prescribed testosterone for low libido. Journal of Sexual Medicine, 6, 1850–1856.
26.
Davison, S.L. & Davis, S.R. (2011). Androgenic hormones and aging − the link with female sexual function. Hormones and Behavior, 59, 745–753.
27.
Eisenegger, C., Haushofer, J. & Fehr, E. (2011). The role of testosterone in social interaction. Trends in Cognitive Sciences, 15, 263–271.
28.
El-Hage, G., Eden, J.A. & Manga, R.Z. (2007). A double-blind, randomized, placebo-controlled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomized women with hypoactive sexual desire disorder. Climacteric, 10, 335–343.
29.
Fogle, R.H., Stanczyk, F.Z., Zhang, X. & Paulson, R.J. (2007). Ovarian androgen production in postmenopausal women. Journal of Clinical Endocrinology & Metabolism, 92, 3040–3043.
30.
Hamilton, L.D. & Meston, C.M. (2010). The effects of partner togetherness on salivary testosterone in women in long distance relationships. Hormones and Behavior, 57, 198–202.
31.
Hayes, D.J. & Greenshaw, A.J. (2011). 5-HT receptors and reward-related behaviour: a review. Neuroscience and Biobehavioral Reviews, 35, 1419–1449.
32.
Hermans, E.J., Bos, P.A., Ossewaarde. L., Ramsey, N.F., Fernandez, G. & Honk J. van (2010). Effects of exogenous testosterone on the ventral striatal BOLD response during reward anticipation in healthy women. Neuroimage, 52, 277–283.
33.
Hermans, E.J., Putman, P. & Honk, J. van (2006). Testosterone administration reduces empathetic behavior: a facial mimicry study. Psychoneuroendocrinology, 31, 859–866.
34.
Hermans, E.J., Putman, P., Baas, J.M, Gecks, N.M., Kenemans, J.L. & Honk J. van (2007). Exogenous testosterone attenuates the integrated central stress response in healthy young women. Psychoneuroendocrinology, 32, 1052–1061.
35.
Hermans, E.J., Ramsey, N.F. & Honk, J. van (2008). Exogenous testosterone enhances responsiveness to social threat in the neural circuitry of social aggression in humans. Biological Psychiatry, 63, 263–270.
36.
Hobbs, A. & Ignarro, L. (1996). Nitric oxide cyclic GMP signal transduction system. Nitric Oxide, Pt B, 269, 134–148.
37.
Hofling, M., Hirschberg, A.L, Skoog, L., Tani, E., Hagerstrom, T., Schoultz, B. von (2007). Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. Menopause, 14, 183–190.
38.
Honk, J. van, Peper, J.S. & Schutter, D.J. (2005). Testosterone reduces unconscious fear but not consciously experienced anxiety: implications for the disorders of fear and anxiety. Biological Psychiatry, 58, 218–225.
39.
Honk, J. van, Schutter, D.J, Hermans, E.J, Putman, P., Tuiten, A. & Koppeschaar, H. (2004). Testosterone shifts the balance between sensitivity for punishment and reward in healthy young women. Psychoneuroendocrinology, 29, 937–943.
40.
Honk, J. van, Schutter, D.J. (2007). Testosterone reduces conscious detection of signals serving social correction: implications for antisocial behavior. Psychological Science, 18, 663–667.
41.
Hull, E.M. & Dominguez, J.M. (2007). Sexual behavior in male rodents. Hormones and Behavior, 52, 45–55.
42.
Joseph, R. (1999). Environmental influences on neural plasticity, the limbic system, emotional development and attachment: a review. Child Psychiatry and Human Development, 29, 189–208.
43.
Kaaks, R., Rinaldi, S., Key, T.J., Berrino, F., Peeters, P.H., Biessy, C. et al. (2005). Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocrine-Related Cancer, 12, 1071–1082.
44.
Karama, S., Lecours, A.R., Leroux, J.M., Bourgouin, P., Beaudoin, G, Joubert, S. et al. (2002). Areas of brain activation in males and females during viewing of erotic film excerpts. Human Brain Mapping, 16, 1–13.
45.
Kenemans, P. & Mooren, M.J. van der (2012). Androgens and breast cancer risk. Gynecological Endocrinology, 28 Suppl 1, 46–49.
46.
Laumann, E.O., Paik, A. & Rosen, R.C. (1999). Sexual dysfunction in the United States: prevalence and predictors. JAMA, 281, 537–544.
47.
Lobo, R.A., Rosen, R.C., Yang, H.M., Block, B., Hoop, R.G. van der (2003). Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertility and Sterility, 79, 1341–1352.
48.
Made, F. van der, Bloemers, J., Ham, D. van, El Yassem, W., Kleiverda, G., Everaerd, W. et al. (2009a). Childhood sexual abuse, selective attention for sexual cues and the effects of testosterone with or without vardenafil on physiological sexual arousal in women with sexual dysfunction: a pilot study. Journal of Sexual Medicine, 6, 429–439.
49.
Made, F. van der, Bloemers, J., Yassem, W.E., Kleiverda, G., Everaerd, W., Ham, D. van et al. (2009b). The influence of testosterone combined with a PDE5-inhibitor on cognitive, affective, and physiological sexual functioning in women suffering from sexual dysfunction. Journal of Sexual Medicine, 6, 777–790.
50.
Mendel, C. (1989). The Free Hormone Hypothesis – a Physiologically Based Mathematical-Model. Endocrine Reviews, 10, 232–274.
51.
Mifsud, A., Ramirez, S. & Yong, E. (2000). Androgen receptor gene CAG trinucleotide repeats in anovulatory infertility and polycystic ovaries. Journal of Clinical Endocrinology & Metabolism, 85, 3484–3488.
52.
Miller, S.L. & Maner, J.K. (2010). Scent of a woman: men’s testosterone responses to olfactory ovulation cues. Psychological Science, 21, 276–283.
53.
Nachtigall, L., Casson, P., Lucas, J., Schofield, V., Melson, C. & Simon, J.A. (2011). Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecological Endocrinology, 27, 39–48.
54.
Nathorst-Boos, J., Floter, A., Jarkander-Rolff, M., Carlstrom, K. & Schoultz, B. (2006). Treatment with percutaneous testosterone gel in postmenopausal women with decreased libido-effects on sexuality and psychological general well-being. Maturitas, 53, 11–18.
55.
Okazawa, H., Yamane, F., Blierm P, & Diksic, M. (1999). Effects of acute and chronic administration of the serotonina(1A) agonist buspirone on serotonin synthesis in the rat brain. Journal of Neurochemistry, 72, 2022–2031.
56.
Pineyro, G. & Blier, P. (1999). Autoregulation of serotonin neurons: Role in antidepressant drug action. Pharmacological Reviews, 51, 533–591.
57.
Poels, S., Bloemers, J., Rooij, K. van, Goldstein, I., Gerritsen, J., Ham, D. van et al. (2013). Toward personalized sexual medicine (part 2): testosterone combined with a PDE5 inhibitor increases sexual satisfaction in women with HSDD and FSAD, and a low sensitive system for sexual cues. Journal of Sexual Medicine, 10, 810–823.
58.
Postma, A., Meyer, G., Tuiten, A., Honk, J. van, Kessels, R.P. & Thijssen, J. (2000). Effects of testosterone administration on selective aspects of object-location memory in healthy young women. Psychoneuroendocrinology, 25, 563–575.
59.
Roney, J.R., Lukaszewski, A.W. & Simmons, Z.L. (2007). Rapid endocrine responses of young men to social interactions with young women. Hormones and Behavior, 52, 326–333.
60.
Rooij, K. van, Bloemers, J., Leede, L. de, Goldstein, I., Lentjes, E., Koppeschaar, H. et al. (2012). Pharmacokinetics of three doses of sublingual testosterone in healthy premenopausal women. Psychoneuroendocrinology, 37, 773–781.
61.
Rooij, K. van, Poels, S., Bloemers, J., Goldstein, I., Gerritsen, J., Ham, D. van et al. (2013). Toward personalized sexual medicine (part 3): testosterone combined with a Serotonin1A receptor agonist increases sexual satisfaction in women with HSDD and FSAD, and dysfunctional activation of sexual inhibitory mechanisms. Journal of Sexual Medicine, 10, 824–837.
62.
Schutter, D.J. & Honk, J. van (2004). Decoupling of midfrontal delta-beta oscillations after testosterone administration. International Journal of Psychophysiology, 53, 71–73.
63.
Secreto, G., Venturelli, E., Meneghini, E., Carcangium M.L., Paolini, B., Agresti, R. et al. (2012). Androgen receptors and serum testosterone levels identify different subsets of postmenopausal breast cancers. BMC Cancer, 12, 599,2407-12-599.
64.
Sherwin, B.B., Gelfand, M.M. & Brender, W. (1985). Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause. Psychosomatic Medicine, 47, 339–351.
65.
Shifren, J..L, Braunstein, G.D., Simon, J.A., Casson, P.R., Buster, J.E., Redmond, G.P. et al. (2000). Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. New England Journal of Medicine, 343, 682–688.
66.
Shifren, J.L., Monz, B.U., Russo, P.A., Segreti, A. & Johannes, C.B. (2008). Sexual problems and distress in United States women: prevalence and correlates. Obstetrics & Gynecology, 112, 970–978.
67.
Simon, J., Braunstein, G., Nachtigall, L., Utian, W., Katz, M., Miller, S. et al. (2005). Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. The Journal of Clinical Endocrinology & Metabolism, 90, 5226–5233.
68.
Slatcher, R.B., Mehta, P.H. & Josephs, R.A. (2011). Testosterone and self-reported dominance interact to influence human mating behavior. Social Psychological and Personality Science, 2, 531–539.
69.
Snabes, M.C., Berry, S., Zborowski, J. & White, W. (2012). Libigel (R) (Testosterone Gel) Safety Study Completes Enrollment and Continues with a Low Cv Event Rate. Journal of Sexual Medicine, 9, 166-.
70.
Snabes, M.C., Zborowski, J. & Simes, S. (2012). Libigel (R) (Testosterone Gel) does Not Differentiate from Placebo Therapy in the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women. Journal of Sexual Medicine, 9, 171-.
71.
Staa, T.P. van & Sprafka, J.M. (2009). Study of adverse outcomes in women using testosterone therapy. Maturitas, 62, 76–80.
72.
Stoleru, S., Gregoire, M.C., Gerard, D., Decety, J., Lafarge, E., Cinotti, L. et al. (1999). Neuroanatomical correlates of visually evoked sexual arousal in human males. Archives of Sexual Behavior, 28, 1–21.
73.
Tops, M., Russo, S., Boksem, M.A. & Tucker, D.M. (2009). Serotonin: modulator of a drive to withdraw. Brain and Cognition, 71, 427–436.
74.
Tuiten, A., Honk, J. van, Koppeschaar, H., Bernaards, C., Thijssen, J. & Verbaten, R. (2000). Time course of effects of testosterone administration on sexual arousal in women. Archives of General Psychiatry, 57, 149–153; discussion 155–156.
75.
Tuiten, A., Honk, J. van, Verbaten, R., Laan, E., Everaerd, W. & Stam, H. (2002). Can sublingual testosterone increase subjective and physiological measures of laboratory-induced sexual arousal? Archives of General Psychiatry, 59, 465–466.
76.
Tuiten, A., Laan, E., Panhuysen, G., Everaerd, W., Haan, E. de, Koppeschaar, H. et al. (1996). Discrepancies between genital responses and subjective sexual function during testosterone substitution in women with hypothalamic amenorrhea. Psychosomatic Medicine, 58, 234–241.
77.
Woolcott, C.G., Shvetsov, Y.B., Stanczyk, F.Z., Wilkens, L.R., White, K.K, Caberto, C. et al. (2010). Plasma sex hormone concentrations and breast cancer risk in an ethnically diverse population of postmenopausal women: the Multiethnic Cohort Study. Endocrine-Related Cancer, 17, 125–134.
78.
Zhang, X., Tworoger, S.S., Eliassen, A.H. & Hankinson, S.E. (2013). Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up. Breast Cancer Research and Treatment, 137, 883–892.
Metagegevens
Titel
Een vernieuwende farmacotherapeutische behandeling voor vrouwen met hypoactive sexual desire disorder
Auteurs
Saskia Poels
Jos Bloemers
Kim van Rooij
Hans Koppeschaar
Berend Olivier
Adriaan Tuiten
Publicatiedatum
01-02-2014
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Neuropraxis / Uitgave 1/2014
Print ISSN: 1387-5817
Elektronisch ISSN: 1876-5785
DOI
https://doi.org/10.1007/s12474-014-0038-z

Andere artikelen Uitgave 1/2014

Neuropraxis 1/2014 Naar de uitgave

Artikel

Kijken naar porno: subcorticale hersenactiviteit weerspiegelt negatieve maar niet positieve seksuele associaties

Artikel

Erotische visuele stimuli deactiveren de primaire visuele cortex bij vrouwen

Artikel

Lifelong premature ejaculatie: een neurobiologische hypothese over erectio praecox, hypererotisch toestandsbeeld en detumescentia praecox

Voorwoord

Woorden vooraf

Events

Erratum

Artikel

Rattenseks als model voor complex seksueel gedrag van mensen